Phase
Condition
Cytomegalovirus Infections
Hearing Impairment
Hearing Loss
Treatment
N/AClinical Study ID
Ages < 99 All Genders
Study Summary
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
Subjects must have or be a family member of a participant with known or non-syndromic SNHL associated with EVA or have evidence of other findings that suggest that EVA might be part of a novel phenotype
There must be at least two participating affected family members with one exception: if there is only one participating affected family member, there must be genetic test results identifying only one pathogenic mutant allele of SLC26A4
Adults must be able to provide informed consent
Minors must have a parent or guardian able to provide consent
Age between 0-99.
Exclusion
EXCLUSION CRITERIA:
Subjects with known exposure to physical or chemical teratogens in utero that could account for their inner ear malformations such as thalidomide or radiation
Any hearing loss that is associated with symptoms which meet the criteria of already known syndromes, such as, branchio-oto-renal (BOR) syndrome, which comprises system malformations and branchial cleft abnormalities and is caused by heterozygous mutations in the EYA1 gene.
Previous genetic testing identifying two pathogenic mutant alleles of SLC26A4.
Prospective study subjects who are cognitively impaired and lack consent capacity, will not be enrolled.
Study Design
Study Description
Connect with a study center
National Institutes of Health Clinical Center
Bethesda, Maryland 20892
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.